Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a RSV challenge study of S-337395
ISRCTN24865912Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of S-337395 in respiratory syncytial virus disease (RSV) (5 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: RSV viral load by qRT-PCR. Started Apr 2024; status: completed.
02
Drugs
S-337395
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on ISRCTN24865912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24865912.